Axelar is a Swedish drug development company developing targeted oral anti-cancer therapies for indications where there are significant unmet medical needs. In 2017 Axelar received orphan drug designation for AXL1717 for the treatment of glioma, which will be the focus of upcoming clinical trials.
GOAL The company aims to develop novel anti-cancer treatments for indications where there are significant unmet medical needs.
BACKGROUND The company was founded based on research performed at Karolinska Institutet, Stockholm and the discovery of a group of compounds that target the IGF-1 receptor signaling pathway without affecting signaling from the closely related insulin receptor. The compound, AXL1717, also possesses other anti-cancer properties.
IPR Axelar’s lead compounds AXL1717 is protected by several patents and patent applications. Patents have been granted in the US, Europe and other key territories.
SHAREHOLDERS The company is owned by The Foundation for Baltic and East European Studies is the largest shareholder in Axelar AB. The remaining shares are owned by the company’s founders and a number of additional investors.